$NRSN News

NeuroSense Announces Pricing of Insider-Led PIPE Financing

NeuroSense Granted Brazilian Patent Covering PrimeC Composition

NeuroSense Therapeutics Granted Patent From Brazilian Patent And Trademark Office Entitled 'Compositions Comprising Ciprofloxacin And Celecoxib'

Reported Friday, NeuroSense Therapeutics Receives Dual Nasdaq Non-Compliance Notices For Minimum Bid Price And $35M Market Value Requirements, Given Until September 29, 2026

NeuroSense Therapeutics Announces Receipt of Nasdaq Notifications Regarding Minimum Bid Price and Market Value Requirements

NeuroSense Therapeutics Reports Year End 2025 Financial Results and Provides Business Update

NeuroSense Therapeutics FY EPS $(0.44) Misses $(0.35) Estimate

NeuroSense Advances Toward Key Regulatory Milestones with Strengthened Data Package and Near-Term Alzheimer's Readout

NeuroSense Announces Pre-NDS Meeting With Health Canada Rescheduled To May 2026 To Gather Additional Clinical Data For PrimeC Lead Candidate; Expects To Report Clinical Results From Alzheimer's Study In Coming Weeks

NeuroSense Announces Pre-NDS Meeting With Health Canada Rescheduled To May 2026 To Gather Additional Clinical Data For PrimeC Lead Candidate; Expects To Report Clinical Results From Alzheimer's Study In Coming Weeks

/C O R R E C T I O N -- NeuroSense/

JAMA Neurology Publishes Results from PARADIGM Phase 2b Trial of PrimeC in ALS Demonstrating Meaningful Clinical Outcomes and Biological Activity

NeuroSense Publishes Phase 2b PARADIGM Results In JAMA Neurology Showing PrimeC Slows ALS Progression, Reduces Complications, Modulates Disease Biomarkers

Roth Capital Initiates Coverage On NeuroSense Therapeutics with Buy Rating, Announces Price Target of $3

PrimeC Long-Term Survival Data to Be Presented at a Leading ALS Scientific Conference

NeuroSense Announces Statistically Significant 65% Reduction in Risk of Death and Greater than 14-Month Median Survival Benefit with PrimeC in ALS

NeuroSense Therapeutics shares are trading lower. The company announced the availability of additional long-term survival data from its PARADIGM Phase 2b clinical trial evaluating PrimeC.

NeuroSense Therapeutics Announces Availability Of Additional Long-Term Survival Data From PARADIGM Phase 2b Clinical Trial Evaluating PrimeC In Patients With ALS

NeuroSense Expands Global IP Protection Strategy With Granted Australian Patent Covering PrimeC Composition

NeuroSense Therapeutics Granted Australia Patent For Its PrimeC